A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation

Koen van Rossem,1 Jenny A Lowe21Stiefel, Research Triangle Park, NC, USA; 2Stiefel, Stockley Park West, Uxbridge, UKBackground: Albaconazole is a novel triazole being developed for the oral treatment of fungal diseases. Once-weekly oral dosing with 400 mg albaconazole for 24 or 36 weeks resulted in...

Full description

Bibliographic Details
Main Authors: van Rossem K, Lowe JA
Format: Article
Language:English
Published: Dove Medical Press 2013-01-01
Series:Clinical Pharmacology : Advances and Applications
Online Access:http://www.dovepress.com/a-phase-1-randomized-open-label-crossover-study-to-evaluate-the-safety-a12086

Internet

http://www.dovepress.com/a-phase-1-randomized-open-label-crossover-study-to-evaluate-the-safety-a12086

Similar Items